Senores Pharma.
Senores Pharma. Q1 FY27 Results & Concall Highlights: Revenue, Margins & Order Book
Q1 FY27 earnings call: what management guided on revenue, margins and order book.
What the Q1 FY27 call signalled
3 of 4 strong
Not discussed on this call: fundraise.
The short version
Target revenue of INR 2,500 to 3,000 crores within 3-4 years. Senores Pharmaceuticals guides for a **50% PAT growth in FY27**, with expectations for growth to continue thereafter, though exact FY28 numbers are premature to specify.
From Senores Pharma.'s Q1 FY27 earnings-call transcript · updated 25 Aug 2026.
Revenue & Sales Performance
- Target revenue of INR 2,500 to 3,000 crores within 3-4 years.
- FY '27 guidance: 30%-40% revenue growth; 50%-60% PAT growth.
- Similar growth trajectory expected post FY '27, though exact FY '28 guidance is premature.
- Growth driven by:
- - Regulated markets: US ANDA portfolio expanding from 30 to 58 approved ANDAs; 23 commercialized; 35 more to launch in 18-20 months.
- - Emerging markets: 500+ current product approvals; 900+ registrations in pipeline.
- - India branded generics: expected to reach INR 50-60 crores sales with 35%-40% EBITDA.
- Production capacity expansion at Apnar and US facilities to support growth.
- Strong pipeline with 39 molecules under development, providing multiyear growth visibility.
- Growth drivers balanced between regulated (~70%) and emerging (~30%) markets, expected to maintain this mix.
Profitability & Margins
See what Senores Pharma. said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- FY27 Capex planned: INR 100-120 crores across subsidiaries, mainly for capacity expansion in oral solids and starting an injectable pilot plant.
- Apnar facility: Expanding with third and fourth production lines to ramp up oral solid manufacturing capacity.
- US plant capacities are also being increased to support regulated market growth.
- Sterile injectable project: Scaled down to a pilot facility with lower cost; full-scale execution pushed to H2 FY27 pending shareholder approval.
- Zoraya Pharma (US subsidiary, B2C arm) expected to commence operations around September-October 2026.
- No major new greenfield facilities planned; focus is on optimizing existing facilities for better return on investment.
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Senores Pharma. said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
- Senores Pharmaceuticals has about 58 approved ANDAs, with 35 approved but yet to be launched.
- There are 39 more ANDAs (molecules) under development, some filed, some to be filed.
- The emerging markets segment has around 500 approved product registrations.
- Additionally, about 900 product registrations are currently in the pipeline, already filed with respective Ministries of Health.
- This robust pipeline forms a strong orderbook, supporting continued growth in both regulated and emerging markets.
- The company aims to leverage this portfolio for sustained revenue growth reaching INR2,500 to INR3,000 crores in 3-4 years.
Senores Pharma. — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest: revenue ₹175 Cr, net profit ₹37 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Senores Pharmaceuticals Ltd's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- Novartis India Ltd (Q1 FY27)
Focused growth in six core therapy areas: cardiology, pain management, women's health, CNS, transplant, and ophthalmology, which contribute 40-50% of…
- IOL Chemicals & Pharmaceuticals Ltd (Q1 FY27)
Expansion plans supported by capex of INR 200-250 crores annually, with 60% towards expansion/new products and 40% towards efficiency improvements. Key concall…
- Innova Captab Ltd (Q1 FY27)
The company is confident of achieving 20%+ volume growth backed by steady ramp-up in Jammu and existing facilities. Key concall takeaways from Innova Captab…
- Glenmark Pharmaceuticals Ltd (Q1 FY27)
Chronic respiratory segment in India showing over 25% growth; oncology and cardiovascular segments also strong. Key concall takeaways from Glenmark…
Frequently Asked Questions
What were Senores Pharma. Q1 FY27 results?
Target revenue of INR 2,500 to 3,000 crores within 3-4 years. Senores Pharmaceuticals guides for a **50% PAT growth in FY27**, with expectations for growth to continue thereafter, though exact FY28 numbers are premature to specify.
What is Senores Pharma. share price analysis?
Senores Pharma. currently shows a strong growth signal based on ranking data. The stock trades at a P/E of 55.1 with a market cap of ₹6,969 Cr. Investors should review the full earnings analysis for detailed insights.
Is Senores Pharma. planning capital expenditure?
FY27 Capex planned: INR 100-120 crores across subsidiaries, mainly for capacity expansion in oral solids and starting an injectable pilot plant.
Keep Senores Pharma. on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and concall transcripts. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.